Pioneering the development
of engineered IgM antibodies
for the treatment of cancer

antibody-solo

IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Sept. 20, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the…

Read More...

IGM Biosciences Announces Pricing of Initial Public Offering

September 17, 2019 at 8:46 PM EDT MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq:…

Read More...

IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the…

Read More...

Multimeric IgM antibodies targeting DR5 are potent and rapid inducers of tumor cell apoptosis and cell death in vitro and in vivo

Read More...

IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors

Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership IGM…

Read More...

IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer

Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience  IGM Biosciences,…

Read More...